RITA CORRERO
INOFEA AG

Context/Overview
Biologics, including mRNA-based therapeutics/vaccines and antibody drug conjugates (ADCs), have demonstrated groundbreaking benefits in healthcare, offering not only preventive measures against viral infections but also targeted therapies with reduced side effects for cancer and autoimmune diseases. Nevertheless, the manufacturing of such Biologics is a sophisticated process with still several challenges to address.

State of the art
The pandemic has triggered a strong interest in mRNA-based vaccines and therapeutics and at the same time has driven the manufacturing of nucleic acids to significant changes. The mRNA vaccine and therapeutic market is expected to reach 85 billion USD in 2030 (1).

Similarly, the development of ADCs has significantly increased in the last decade. The size of the ADCs market is expected to grow from 3.2 billion USD in 2020 to 20.0 billion USD in 2028.

Manufacturing and purification processes of Biologics are still not efficient and rather costly. Current limitations in the manufacturing of Biologics are the limited scala ...